Lu Rebecca, Morphey Ashley, Diaz Felicia, Chen Jessica, Razmandi Azadeh, Richards Tiffany
From The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Adv Pract Oncol. 2023 May;14(4):300-306. doi: 10.6004/jadpro.2023.14.4.4. Epub 2023 May 1.
While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for more treatment modalities remains, as patients who are refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies have a median survival of only 5.8 to 13 months. Belantamab mafodotin, a first-in-class antibody-drug conjugate, was approved by the US Food and Drug Administration in 2020 for patients with relapsed or refractory myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It produced an overall response rate of 31%, and the median progression-free survival was 2.9 months when administered as a single agent. While generally well tolerated, ocular toxicities were a notable adverse event reported. In this article, we discuss the response data, toxicity profile including ocular toxicities, and treatment management.
虽然在多发性骨髓瘤的治疗方面已取得显著进展，但治疗选择仍然有限且明确，大多数患者最终仍会死于该疾病。由于对蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体难治的患者中位生存期仅为5.8至13个月，因此对更多治疗方式的需求仍然迫切。Belantamab mafodotin是一种一流的抗体药物偶联物，于2020年被美国食品药品监督管理局批准用于复发或难治性骨髓瘤患者，这些患者此前至少接受过四种治疗，包括抗CD38单克隆抗体、蛋白酶体抑制剂和免疫调节剂。它产生了31%的总缓解率，作为单一药物给药时的中位无进展生存期为2.9个月。虽然总体耐受性良好，但眼部毒性是报告的一个显著不良事件。在本文中，我们讨论了缓解数据、包括眼部毒性在内的毒性特征以及治疗管理。
